Cannabinoids in inflammatory bowel diseases: review and meta-analysis of RCTs

Introduction and clinical context

The study Cannabinoids in inflammatory bowel diseases: review and meta-analysis of RCTs (Biomedicines (MDPI) · 2022) is part of the scientific research on the use of cannabinoids in inflammatory bowel disease.

In inflammatory bowel disease (IBD) — which includes Crohn's disease and ulcerative colitis —, cannabinoids are studied for their possible effect on symptoms and quality of life. Trials with CBD-rich cannabis suggest a clinical response and symptomatic relief in some patients, although without consistently demonstrating endoscopic improvement (mucosal healing). The endocannabinoid system is present in the gastrointestinal tract and takes part in regulating inflammation and motility.

Understanding what science shows about the use of cannabinoids in inflammatory bowel disease helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This scientific review gathered and critically appraised the available literature on the topic. Systematic review and meta-analysis of randomized trials on cannabinoids in IBD (Crohn's and ulcerative colitis). As a synthesis of multiple studies, it offers a more robust picture than isolated reports, though it depends on the quality of the included works. For clinical practice, syntheses like this help calibrate expectations and support clinical decisions.

Mechanism of action and safety

In the gastrointestinal tract, the endocannabinoid system regulates motility, secretion and inflammation, with CB1/CB2 receptors in the intestinal wall — the basis for studying cannabinoids in IBD; CBD adds an anti-inflammatory effect without psychoactivity. Regarding safety, drowsiness and dizziness are observed, with attention to drug interactions. It is important to note that symptomatic relief is not equivalent to controlling inflammation (mucosal healing). Use should be adjuvant and monitored by the gastroenterologist, without replacing the baseline therapy.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (Biomedicines (MDPI) · 2022). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis treat Crohn's disease?

Studies report symptom relief, but without consistent endoscopic healing; use is adjuvant and monitored.

Does the gut have cannabinoid receptors?

Yes. The endocannabinoid system is present in the gastrointestinal tract and regulates inflammation and motility.